Transaction #14748 · Form 4 · 0001643653-25-000007
NEUROCRINE BIOSCIENCES INC · Exercise / conversion · Common Stock
NEUROCRINE BIOSCIENCES INC · Transacted November 28, 2025 · Filed December 2, 2025
What does this filing report?
An SEC Form 4 filing for NEUROCRINE BIOSCIENCES INC records an exercise / conversion involving Common Stock on November 28, 2025. The reported quantity was 5,970. The filing date is December 2, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- NEUROCRINE BIOSCIENCES INC
- Company CIK
- 0000914475
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 5,970
- Reported price
- 35.99
- Reference value
- 214,860.3
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 50,863
- Ownership description
- Not reported
- SEC acceptance time
- Dec 2, 2025, 5:21 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- BENEVICH ERIC ↗
Chief Commercial Officer
CIK 0001643653
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan
- F3
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4
- The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.